Spherocytosis and elliptocytosis

Clinical picture

Spherocytosis and elliptocytosis are inherited blood disorders characterised by spherical- or ellipsoid- shaped red blood cells and anaemia. These abnormally shaped red blood cells are degraded faster than normal red blood cells. Spherocytosis and elliptocytosis belong to the group of haemolytic anaemias and are often associated with jaundice and an enlarged spleen.

In hereditary spherocytosis and elliptocytosis, the cell membrane surface area of the red blood cells have an aberrant shape. A defect (mutation) in a gene (a sequence of DNA) is the underlying cause, leading to aberrant membrane proteins of red blood cells. Normal red blood cells have a biconcave disc shape. In spherocytosis, the red blood cells are sphere-shaped, called spherocytes. In elliptocytosis, the red blood cells are oval (elliptical) and are called elliptocytes. In this setting, the exchange of gasses (oxygen and carbon dioxide) is impaired and the membrane of the red blood cells is less flexible than that of normal red blood cells. The abnormal shaped cells are broken down by the spleen faster than normal, healthy red blood cells. The symptoms of spherocytosis/elliptocytosis are the result of the deficiency of red blood cells, as well as the abundance of these cells in the spleen.

How often are spherocytosis and elliptocytosis diagnosed?

Both disorders affect men and women equally. Hereditary spherocytosis is the most common form of haemolytic anaemia. At least 1 in 5,000 people in Northern Europe are affected by this disease. The prevalence of hereditary spherocytosis in other ethnic backgrounds is not known.

Hereditary elliptocytosis is very rare and most common in the African and Mediterranean population. Haemolysis of the red blood cells is generally hardly present or even absent, and there is only mild anaemia. An enlarged spleen, however, is common. People whose spleen is removed (splenectomy) have a normal life expectancy.

Symptoms

Most people with spherocytosis or elliptocytosis have only mild symptoms or no symptoms at all. Between family members, large differences in severity of the disease can occur. The severity of symptoms in an individual patient can also differ over time.

The onset of symptoms of hereditary spherocytosis is most common during childhood. About seven in ten patients experience only mild to moderate symptoms, while other patients have severe or even life threatening manifestations of the disease. Common symptoms of spherocytosis/elliptocytosis are:

  • Fatigue, weakness, shortness of breath, headache and pale skin, due to deficient red blood cell levels (anaemia).
  • Jaundice (yellowish skin, white of the eye), due to high bilirubin levels in the blood. High bilirubin levels are a consequence of the increased break-down of the red blood cells and the degradation of haemoglobin. With this, bilirubin is released, causing the skin and the white of the eye to turn yellow, and the urine darker.
  • Stomach ache. Painful gallstones can develop due to the high bilirubin levels in the blood.
  • Enlarged spleen (splenomegaly). Due to the increased break down of red blood cells.
  • Growth recession and delayed puberty.
  • High susceptibility to life-threatening infections such as pneumonia, meningitis, and malaria, due to splenic sequestration (damage to the spleen) or removal of the spleen.
    • Viral infections can cause a reduced production of red blood cells (aplastic crisis).

The symptoms of spherocytosis are generally more severe than those of elliptocytosis.

Cause

Both spherocytosis and eliptocytosis are disorders that inherit (mostly) in an autosomal dominant manner. Autosomal means that it is not linked to the X-chromosome (sex chromosome). Men and women are therefore equally affected by the disease. Dominant inheritance means that just one abnormal gene from a parent can cause the disease. The inheritance of hereditary spherocytosis can also be autosomal recessive. In this case both copies of the gene (one from each parent) must carry a defect to cause the disease. In 25% of cases, spherocytosis is the result of spontaneous defects in the gene.

At least five genes are associated with hereditary spherocytosis. In about half of the cases a defect in the ANK1 gene is found. These five genes code for proteins that are present on the cell surface (cell membrane) of red blood cells. Mutations (defects) in these membrane proteins may lead to abnormal and abnormally shaped cells.

Diagnosis

Spherocytosis and elliptocytosis are diagnosed on the basis of presence of the disease in family members, the characteristic symptoms of the patient, and laboratory tests. A differential diagnosis is used to exclude other conditions with great similarity to the symptoms of spherocytosis and elliptocytosis. When there is clinical suspicion of these disorders, the following tests are helpful to make the diagnosis:

  • Structured patient history, taking into account their previous medical history and presenting complaints.
  • Physical examination.
  • Blood tests.
    • Complete blood count. Determine nature and severity of anemia.
    • Reticulocyte (young red blood cells) count. Determine reticulocyte production index in the bone marrow. A person with sickle cell disease has a higher production index due to the increased destruction of red blood cells.
    • Blood smear. Test to check on abnormally shaped red blood cells.

A patient who is diagnosed with haemolytic anaemia will undergo additional blood tests to determine whether he or she had spherocytosis, elliptocytosis or another form of haemolytic anaemia:

  • Osmotic fragility test, can be used to search for abnormally vulnerable red blood cells, e.g. present in hereditary spherocytosis and elliptocytosis.
  • Electrophoresis of membrane proteins, and other, more specific, analyses.

Treatment

Because of the hereditary nature of the diseases, hereditary spherocytosis and elliptocytosis are incurable. Patients who have only mild symptoms, do not need treatment. For patients with moderate to severe symptoms, treatment options include:

  • Folic acid for moderate anaemia. Stimulates the production of red blood cells.
  • Erythropoietin for severe anaemia in the first year of life.
  • Blood transfusion for children up to the age of 12 months with severe anaemia in combination with exhaustion and/or retarded growth.
  • In cases of severe haemolysis, a blood transfusion can relieve symptoms.
  • Newborn babies with severe jaundice and brain damage (kernicterus) due to the buildup of bilirubin in the brain may need phototherapy (light treatment) and/or exchange transfusions.
  • Removal of the spleen (splenectomy), only when strictly necessary. After removal of the spleen, the life span of the red blood cells is extended to normal. The symptoms will (almost) disappear. Children can undergo splenectomy after their sixth to ninth birthday, because young children have a high risk of infections.
  • Antibiotics and vaccinations for increased risk of (severe) infections after splenectomy. The spleen plays an important role in fighting infections. Vaccination with Pneumovax against pneumococcal infections is mandatory, as well as long-term antibiotics to prevent a bacterial infection.

Additional information

Clinical picture

Symptoms

Cause

Diagnosis

Treatment

Patient organisations